FLAURA2
-
Osimertinib Plus Chemotherapy Shows Unprecedented Survival Benefit in EGFR-Mutated Advanced Lung Cancer
The FLAURA2 Phase III trial demonstrated that TAGRISSO® (osimertinib) combined with chemotherapy significantly improved overall survival (OS) compared to TAGRISSO monotherapy in 1st-line EGFRm NSCLC. The combination therapy achieved a median OS of 47.5 months versus 37.6 months with monotherapy, reducing the risk of death by 23%. The safety profile was manageable, reinforcing TAGRISSO as a standard of care and backbone therapy across EGFRm lung cancer stages.
